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Abstract
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized
by platelet destruction resulting from autoantibodies against platelet proteins, particularly platelet
glycoprotein IIb/IIIa. Heat shock proteins (Hsp) have been shown to be major antigenic
determinants in some autoimmune diseases. Antibodies to Hsps have also been reported to be
associated with a number of pathological states.
Methods: Using western blot, we measured the levels of the 60 kDa heat shock protein (Hsp60)
and of the inducible 71 kDa member of the Hsp70 family (Hsp71) in lymphocytes and the presence
of antibodies against these hsps in plasma of 29 pediatric patients with ITP before the treatment
and in 6 other patients before and after treatment.
Results: Interestingly only one out of 29 patients showed detectable Hsp60 in lymphocytes while
this heat shock protein was detected in the 30 control children. Hsp71 levels were slightly lower
in lymphocytes of patients with ITP than in controls (1567.8 ± 753.2 via 1763.2 ± 641.8 integrated
optical density (IOD) units). There was a small increase of Hsp71 after recovery from ITP. The
titers of plasma antibodies against Hsp60 and Hsp71 were also examined. Antibodies against Hsp71
were more common in ITP patients (15/29) than in control children (5/30). The titer of anti-Hsp71
was also higher in children patients with ITP. The prevalence of ITP children with antibodies against
Hsp71 (51.7%) was as high as those with antibodies against platelet membrane glycoproteins
(58.3%).
Conclusions: In summary, pediatric patients with ITP showed no detectable expression of Hsp60
in lymphocytes and a high prevalence of antibody against Hsp71 in plasma. These changes add to
our understanding of the pathogenesis of ITP and may be important for the diagnosis, prognosis
and treatment of ITP.
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Background
Immune thrombocytopenic purpura (ITP) is an autoim-
mune disease characterized by a low platelet count sec-
ondary to accelerated platelet destruction by antiplatelet
antibodies that generally recognize platelet membrane
glycoproteins (GPs) [1]. The triggering or immunogenic
stimulus involved and the role of antiplatelet antibodies
in the disease remain unclear. There is an unbalanced
immune response due to inflammation (i.e., viral infec-
tion, autoimmunity), or to exposure to environmental
agents (i.e., drug, H2O2) [2-6]. Whether the stimulus is
endogenous, i.e. truly "self" or exogenous ("non-self") is
unknown. Some recent evidence argues for an immune-
mediated mechanism in ITP-increased HLA-DR expres-
sion, defects in cellular and humoral immunity, and spe-
cific autoantibody production. There are several forms of
management of ITP ranging from drugs such as corticos-
teroids, a variety of immunosuppressants and immu-
noglobulins to splenectomy [2,6,7]. However some
patients may be receiving unnecessary treatment espe-
cially in the case of pediatric patients [8] as the cause and
etiopathogenesis of ITP remain unknown.
Heat shock proteins (Hsp) are highly conserved proteins
found in prokaryotes and eukaryotes. Induction of Hsps
can be triggered by many stresses. These include exposure
to supraoptimal temperatures (heat shock) and to various
chemicals (xenobiotics, drugs, growth factors, hormones).
Pathological states incurring during viral, bacterial or par-
asitic infections, fever, inflammation, malignancy or
autoimmunity, can also induce an increase in synthesis of
Hsps [9-12]. Many Hsps are also expressed at low levels
under normal physiological conditions. Hsps are usually
grouped into several families (Hsp110, Hsp90, Hsp/
Hsc70 (Hsc: Heat shock cognate), Hsp60, Hsp47 and the
small Hsps (Hsp10-30) on the basis of their apparent
molecular masses after sodium dodecyl sulphate polyacr-
ylamide gel electrophoresis (SDS-PAGE). Hsps can act as
intracellular chaperones of naive, aberrantly folded or
mutated proteins, as stimulators of cytokine signal trans-
duction cascades, as well as in cytoprotection against the
stress stimuli described above [11,13-15]. A role of Hsps
in the inflammatory response is suggested by different
findings. Hsps participate in cytokine signal transduction
and in the control of cytokine gene expression [16]. Hsps
enhance antigen presentation to T lymphocytes, can be
displayed on the surface of cells and may be important in
targeting cytotoxic cells [16,17]. Moreover, recent investi-
gations also indicate that Hsps have the ability to modu-
late the cellular immune response since as cellular
chaperones, they participate in transport through the var-
ious cellular compartments. Thus Hsps may act in transfer
of peptides between cellular compartments, and in bind-
ing endogenous antigenic peptides and transporting them
to the major histocompatibility complexes [18-20]. Hsps
have also been reported to be involved in tumorogenesis
and in inflammation [21-23].
Many investigations have shown that Hsps and autoanti-
bodies to these proteins play a role in the pathogenesis
and/or prognosis of certain diseases [24-31]. Since an
important component of ITP is mediated by autoantibod-
ies, we decided to examine if antibodies against Hsps
could be detected in pediatric patients with ITP. We also
checked if ITP was accompanied by fluctuations in the lev-
els of Hsp60, of the inducible member of the Hsp70 fam-
ily referred to here as Hsp71 and if the expression of these
Hsps changed after recovery from ITP. The data show that
Hsp60 is not detectable in lymphocytes of most pediatric
ITP patients. Whether the expression of Hsp60 was much
lower or totally absent in the ITP children is unknown at
the moment. Finally these patients show a high preva-
lence of antibody against Hsp71 that may be of clinical
significance.
Methods
Subjects and groups
The present study comprised two different groups. The
first ITP group consisted of 29 ITP pediatric patients aged
from 7 to 10 years (male: 18, female: 11) and was con-
ducted from March to November of 2000 in Wuhan. The
second group consisted of 6 different ITP pediatric
patients aged from 7 to 10 years and was conducted in
March and April of 2001. All patients were diagnosed
according to criteria and principles of management of ITP
defined by the Chinese Association of Hematology. This
diagnosis is mainly based on the medical history, symp-
toms and signs, physical examination, peripheral blood
smear, and bone marrow aspiration. Patients who were
referred with bleeding complaints (easy bruising, pur-
pura, mucosal bleeding) and had isolated thrombocyto-
penia with no history of other clinical conditions that can
cause thrombocytopenia were included in our investiga-
tion. At the time of the ITP diagnosis, patients were
excluded from further study if they had a history or clini-
cal findings of antiphospholipid syndrome, systemic
lupus erythematosus, other autoimmune disorders,
acquired immunodeficiency syndrome, or malignancies.
The control group comprised 30 children (15 males, 15
females) aged from 7 to 8 years (mean age: 7.5) who had
no diseases after physical examination and had no history
of respiratory and virus infection in the preceding two
weeks. We also measured changes of Hsp71 levels in lym-
phocytes of the second group of 6 patients with ITP at
admission and after recovery. Treatments consisted of
dexamethasone administration followed by prednisone.
None of the patients received blood transfusion.BMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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Evaluation of health status
Health status was evaluated in all patients and controls
using a questionnaire and by clinical examination and
laboratory determinations. The questionnaire designed
according to diagnostic criteria and principles of ITP, with
emphasis on disease history including family history,
symptoms, use of drug and food, was answered by the
child and/or parent. The clinical examination included a
general examination (signs), weight, height, pulse, oral
temperature, electrocardiography and chest x-ray. Labora-
tory tests included the regular analyses of blood and urine
(haemoglobin, blood typing, platelet and white blood
cell count) and, hepatic functional tests (GPT, GOT, hep-
atitis B antigens and antibodies).
Detection of Hsp60 and Hsp71 in lymphocytes
Blood samples were collected from all pediatric ITP
patients before any treatment was given. Additional blood
samples were collected from the second group of 6
patients after treatment. About 5 ml of venous blood were
collected and divided into two aliquots, one to separate
plasma and lymphocytes for Hsp analysis and the other
aliquot for the routine laboratory tests mentioned above.
Plasma from heparinized whole blood was collected, sed-
imented cells suspended in 3.0 ml of normal saline and
lymphocytes were isolated using Ficoll-Hypaque (Bio-
chemical Reagent Co., Shanghai, China). The collected
lymphocytes were washed twice with PBS, counted and
the concentrations of lymphocytes adjusted to 10,000 per
ul with PBS. 10 ul of lymphocyte suspension was centri-
fuged and cells lysed in SDS-sample buffer by boiling at
100°C for 5 min, and proteins loaded on SDS-PAGE gels
as described previously [28-30]. After electrophoresis,
proteins were transferred electrophoretically to nitrocellu-
lose membranes [28-30,32]. Transfer was monitored by
staining with Ponceau Red. The membrane was saturated
with blocking buffer (PBS containing 5% skim milk pow-
der) for 1 h at 37°C with gentle agitation and washed with
PBS-0.05% Tween 80 for 5 min. It was then incubated at
37°C for 1 h with gentle agitation with rabbit anti-human
Hsp60 or anti-human Hsp71 antibodies [see [32]] diluted
1:1000 in PBS containing 5% skim milk powder. After
washing the membranes six times (6 × 10 min) with 10 ml
PBS-0.05% Tween 80, horseradish peroxydase (HRP) con-
jugated goat anti-rabbit IgG in blocking buffer (1:1000)
was added and the membranes further incubated at 37°C
for 1 h. Membranes were finally washed four times with
10 ml PBS-0.05% Tween 80. The presence of Hsp60 and
Hsp71 was revealed using DAB (3,3-diaminobenzidine
tetrahydrochloride) buffer for 3–5 min [29,30,32]. Hsp60
and Hsp71 were quantified using an imaging densitome-
ter (Shimadzu CS-930, Shimadzu, Japan) and integrated
optical density (IOD) was used to represent the relative
levels of these two proteins.
Determination of antibodies to Hsp60 and Hsp71 in 
plasma of subjects
Recombinant human Hsp60 was obtained through the
expression of human Hsp60 cDNA in Escherichia coli BL2
(DE3) cells using a pET vector. Recombinant inducible
human Hsp71 was obtained through the expression of the
human cDNA coding for the inducible Hsp71 in NaCl-
induced E. coli GJ1168 cells using pET30 as expression
vector [32,33]. Approximately 10–15 µg of recombinant
human Hsp60 or Hsp71 was loaded on each SDS-PAGE
gel without combs and transferred electrophoretically to
nitrocellulose membranes [28]. The band containing
Hsp60 or Hsp71 was cut into 2 mm × 3 mm pieces and
marked with a small red dot on the protein side of the
membrane. The pieces were placed in individual wells of
an ELISA plate, rinsed with PBS, and saturated with 100 µl
of blocking buffer (PBS containing 5% skim milk powder)
for 1 h at 37°C with gentle agitation and washed with
PBS-0.05% Tween 80 for 5 min. The plasma diluted 1:10,
1:20, 1:40 or 1:80 in 100 µl PBS containing 5% skim milk
powder was incubated with the nitrocellulose membrane
pieces at 37°C for 2 h with gentle agitation. After washing
the membranes six times (10 min each) with 200 µl PBS-
0.05% Tween 80, 100 µl of HRP-conjugated goat anti-
human IgG (Sigma) in blocking buffer (1:2500) was
added and the incubation continued at 37°C for 1 h.
Membranes were washed six times (10 min) with 200 µl
PBS-0.05% Tween 80. The presence of antibodies to
Hsp60 or Hsp71 was revealed using DAB (3,3-diami-
nobenzidine tetrahydrochloride) buffer for 3–5 min. A
brown band on the membrane piece is regarded as posi-
tive and no colour as negative [30].
Statistical analyses
Results were expressed as the mean ± standard deviation
(SD) of n samples. Where appropriate, the probability of
significant differences between 2 groups for quantity was
determined by the unpaired Student t test. Comparison
between groups for frequency of an event was done by the
Chi-square test/Fisher exact test. P < 0.05 was considered
significant. All data were analysed using Excel 2000
(Microsoft Corporation, Seattle, USA) and the Statistical
Package for Social Sciences (SPSS Inc, Chicago, USA)
software.
Results
Clinical features of ITP pediatric patients and treatment
A blood routine was performed on all pediatric patients
with ITP, As expected, the number of white blood cells
(7.4 ± 3.3 × 109/L) and the concentration of haemoglobin
(107 ± 16 g/L, range 93–138) while a bit low in some
patients with ITP, did not differ significantly from that of
controls (range 112–140 g/l) and were within normal val-
ues (4 to 10 × 109/L and 110 to 160 g/L respectively).
However the mean number of platelets (32 ± 26, range 1.0BMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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to 82.0 × 109/L) was significantly lower than its normal
value (100 to 300 × 109/L) and is in the abnormal range.
There was no difference in the number of platelets
between male and female patients with ITP. Table 1 sum-
marizes the clinical information on the 29 individual
pediatric patients. Most patients (23/29) presented with
acute ITP. Treatment was initiated with dexamethasone
followed by prednisone in all cases. Intravenous gamma
globulin (IVIG) was only given in very severe cases. Vita-
min C was also provided depending on the condition of
the patient (data not shown).
Levels of Hsp60 and Hsp71 in lymphocytes
Aberrant expression of Hsps has been associated with
many disease states [24,25]. We therefore determined the
levels of Hsp60 and the inducible Hsp71 in lymphocytes
of patients with ITP by Western blot in order to find out if
there was any association between Hsp expression and
ITP. Figure 1 shows examples of Western blots for Hsp60
and Hsp71 in lymphocytes of pediatric patients with ITP
and in controls. As can be seen, Hsp60 was not detected
in lymphocytes of pediatric patients with ITP while there
was a variable but detectable expression of this Hsp in all
controls (Fig. 1A). Throughout the present investigation,
we found only one patient out of 29 (Patient no 17, Table
1) who had a detectable level of Hsp60, while this Hsp
was detected in all 30 individuals from the control group.
The expression of Hsp60 is significantly different (P  <
0.0001) between ITP and control groups. Figure 1B shows
the expression level of Hsp71 in the same patients with
ITP and in controls. The relative values of Hsp71 were
quantified using an imaging densitometer and are given
in IOD units in Table 1. Patients with ITP tended to have
a slightly lower level of Hsp71 (1567.8 ± 753.2 IOD units)
but this difference with controls (1763.2 ± 641.8 IOD
units) was not statistically significant. Patients with the
acute form had a higher mean value (1627 ± 786 IOD
units, range 700–4000) than those with the chronic form
(1340 ± 391 IOD units, range 880–1900). This difference
was not significant (P = 0.398).
Table 1: Summary of data obtained for individual pediatric patients with ITP
NO Gender Age Diagnosis BPC Hsp71 Hsp60 Anti-Hsp71 Anti-Hsp60
1 F 7 acute 76 900 ND 80 -
2 M 7 acute 38 2120 ND 20 -
3F 7 a c u t e 5 1 4 1 0N D - -
4 F 8 acute 43 860 ND - -
5 M 8 acute 2 990 ND 20 -
6 M 8 acute 33 700 ND 80 -
7M 8 a c u t e 2 1 2 0 0N D 8 0 -
8M 8 a c u t e 1 1 5 8 0N D - -
9F 8 a c u t e 9 2 4 9 0N D - -
10 F 8 acute 46 1910 ND - -
11 M 8 acute 6 1250 ND 80 -
12 M 8 acute 56 1570 ND 80 -
13 M 9 acute 50 1020 ND - -
14 M 9 acute 82 900 ND 80 -
15 F 9 acute 19 1000 ND - -
16 M 9 acute 18 1600 ND 40 80
17 M 9 acute 64 2590 DET - -
18 M 10 acute 23 1790 ND 20 -
19 F 10 acute 67 880 ND - -
20 F 10 acute 26 4000 ND 80 -
21 M 10 acute 44 1850 ND - 40
22 F 10 acute 73 2210 ND - -
23 M 10 acute 11 2600 ND 20 10
24 M 7 chronic 4 1230 ND - -
25 M 8 chronic 4 880 ND 80 -
26 M 8 chronic 25 1700 ND - -
27 F 9 chronic 73 1030 ND - -
28 M 10 chronic 5 1300 ND 80 -
29 F 10 chronic 4 1900 ND 20 -
M: Male; F: Female; BPC: blood platelets counts; ND: not detected; DET: detected; -: negative. All blood samples were collected before medication 
was started.BMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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Changes of Hsp60 and Hsp71 in lymphocytes before and 
after recovery
To find out if changes in Hsp levels were related to the
state of the disease, we compared Hsp60 and Hsp71 levels
in lymphocytes of a second group of six pediatric patients
with ITP at admission to the hospital (before) and upon
release after treatment. These six patients were hospital-
ized for approximately 3 weeks and were given treatments
similar to the other ITP patients. None of these 6 patients
showed expression of Hsp60 either before or after treat-
ment. In the case of Hsp71, there were changes and the
level of Hsp71 was higher after three weeks of treatment
for ITP (1951 ± 753 IOD units) than before (1160 ± 727
IOD units) (P  = 0.094) (Table 2). This increase was
accompanied by an increase of platelet count (from 35.0
± 30.8 to 94.5 ± 69.5 × 109/L, P = 0.084) (Table 2). We
also analysed the changes in the Hsp71 levels and platelet
counts in these patients. As illustrated in Figure 2, five of
the six patients showed an increase in the expression lev-
els of Hsp71 and in platelet counts after treatment while a
decrease of platelet counts was noted in one patient.
Presence of plasma antibodies against Hsp60 and Hsp71 in 
patients and controls
The presence of antibodies against Hsps has been reported
in a number of diseases and it has been suggested that
Hsps might be involved in the pathogenesis of the dis-
eases and/or be of use for disease prognosis [28-31,34].
Since there were no available data for pediatric patients
with ITP, we next determined if these patients had anti-
bodies to the inducible Hsp71 and to Hsp60. As shown in
Table 3 and 4, antibodies against Hsp60 and Hsp71 were
Detection of Hsp60 and Hsp71 in lymphocytes of patients with ITP and in controls by Western blot Figure 1
Detection of Hsp60 and Hsp71 in lymphocytes of patients with ITP and in controls by Western blot A: Examples 
of detection of Hsp60. Lane 1:Protein marker; Lane 2–8: Patients with ITP; Lane 9–14: controls. B: Examples of detection of 
Hsp71. Lane 1:Protein marker; Lane 2–8: Patients with ITP; Lane 9–14: controls.
A
B
Hsp60
Hsp71
M
ITP ControlBMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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found in both normal children and in ITP patients. Over
50% of ITP patients had a positive reaction to Hsp70 as
compared to 16.7% of controls (P  < 0.05) (Table 3).
Moreover the titer of these antibodies was higher with
more than half of the patients (9/15) showing a positive
reaction at a dilution of 1:80. Figure 3 shows a compari-
Table 2: Changes of blood platelets counts and Hsp71 levels in pediatric patients with ITP at admission and after treatment
NO Gender Age Diagnosis At admission After treatment
BPC Hsp71 BPC Hsp71
1 F 10 acute 73 1030 99 1850
2 M 10 acute 6 200 69 3060
3 F 8 acute 29 1000 230 2600
4 M 10 acute 6 730 37 1800
5 F 10 acute 75 1090 23 1790
6 M 8 acute 57 1310 73 2210
M: Male; F: Female; BPC: blood platelets counts. Hsp71 values are given in integrated optical density units (see methods)
Changes in the association of Hsp71 versus platelets count in patients with ITP before and after treatment Figure 2
Changes in the association of Hsp71 versus platelets count in patients with ITP before and after treatment.
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son of platelet number in the 29 ITP patients with the
dilution of antibodies against Hsp71. Interestingly, the
platelet counts of ITP patients showing no antibody
against Hsp71 are significantly higher than those positive
for antibody against this Hsp (42.8 ± 27.4 vs 21.4 ± 21.7
× 109/L, P < 0.05). Finally as shown in table 4, there are
no differences in the incidence of antibodies against
Hsp60 between patients with ITP and matched controls (P
> 0.05).
The presence of antibodies against Hsp71 did not seem to
be related to the form of ITP. Three of the six patients with
the chronic form showed antibodies to Hsp71 as com-
pared to 13 out of the 23 patients presenting with the
acute form. The majority of patients in both groups had
titers of anti-Hsp71 of 1:80 (66% for chronic and 61% for
acute) (see Table 1).
Discussion
Many investigations have shown that the aberrant expres-
sion of Hsps or the presence of antibodies against Hsps
may be involved in the pathogenesis of many diseases
and/or may be of use for prognosis and treatment
[24,25,28-31,34]. ITP is an autoimmune diseases caused
by platelet destruction resulting from autoantibodies
against platelet surface proteins, particularly platelet glyc-
oprotein IIb/IIIa. However, how antibodies against plate-
Table 3: Presence of plasma antibodies against Hsp71 in patients with ITP and controls.
Groups Number of 
children
Dilution of antibodies against Hsp71 (n and Percentage)
negative positive 1:10 1:20 1:40 1:80
Control 30 25 (83.3) 5(16.7) 0(0) 3(10.0) 0(0) 2 (6.7)
ITP 29 14(48.3) * 15(51.7) * 0(0) 5(17.2) 1(3.4) 9 (31.0) *
*P < 0.05, compared with control; n: represents the number of children at different dilutions of antibodies against Hsp71.
Table 4: Presence of plasma antibodies against Hsp60 in patients with ITP and control.
Groups Number of 
children
Dilution of antibodies against Hsp60 (n and Percentage)
negative positive 1:10 1:20 1:40 1:80
Control 30 28(93.3) 2(6.7) 0(0) 0(0) 1(3.3) 1(3.3)
ITP 29 26(89.7) 3(10.3) 1(3.4) 0(0) 1(3.4) 1 (3.4)
n: represents the number of children at different dilutions of antibodies against Hsp60.
Distribution of platelet counts (×109/L) of the 29 ITP patients  versus the titer of antibodies against Hsp71 Figure 3
Distribution of platelet counts (×109/L) of the 29 ITP patients 
versus the titer of antibodies against Hsp71.BMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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lets are produced and how platelets are destroyded
remains unknown. Hsps may be of importance in both
immune and inflammatory responses. Whether patients
with ITP exhibit different levels of Hsps and antibodies
against Hsps has only now been examined.
Our data on a group of 29 pediatric patients with ITP
show that there is a slightly lower level of Hsp71
(although not statistically significant) in lymphocytes of
patients compared with controls (1567.8 ± 753.2 versus
1763.2 ± 641.8 IOD units). Interestingly, Hsp60 was only
detected in 1 of the 29 pediatric patients with ITP in a
western blot assay under conditions where this Hsp was
detected in all controls. These data are likely to be of clin-
ical interest for the following reasons. Firstly, Hsps can be
induced by a wide variety of environmental stresses and
pathological stimuli such as viral, bacterial or parasitic
infections, fever, inflammation, malignancy and autoim-
munity. Many of these conditions may contribute to the
pathogenesis of ITP and some can also cause an imbal-
ance of the immune response and autoimmune diseases
[2-6]. Interestingly, we did not find any induction of Hsps
in these patients. Secondly, induced Hsps can protect
cells, organs and organisms against many damages caused
by these stresses [35-44]. A low level or absence of Hsps
might render cells more sensitive to such stresses.
Since Hsps also play an important role in the immune
response, they could serve as an early warning to the host's
immune response during the onset of disease [45]. Hsps
require no adjuvant to confer immunogenicity to bound
peptides as if they possessed an intrinsic "danger" signa-
ture [46]. This "danger signal" alerts the immune system
to the death of a cell under stress and the role of Hsps as
protein carriers allows the immune effector cells to survey
the peptides released by the stressed cell and to activate
against new or unrecognized peptides carried by Hsps
[18]. Hsp60 and Hsp71 not only shuttle immunogenic
peptides [47] but can also activate antigen-presenting cells
[16,19]. These studies demonstrating the importance of
Hsps in immune response, indicate that a low expression
of Hsps (i.e absence of Hsp60 in lymphocytes of patients
with ITP) may be related to the formation of autoantibod-
ies against platelets. An emerging body of data supports a
role for Hsps in the inflammatory response: Hsps partici-
pate in cytokine signal transduction and in the control of
cytokine gene expression [16], enhance antigen presenta-
tion to T lymphocytes, and Hsps displayed on the surface
of cells are important for targeting cytotoxic cells [17].
Vabulas et al. [46] reported that endocytosed human and
chlamydial Hsp60 use toll-like receptor 2 and 4 to activate
the toll/interleukin-1 receptor signaling pathway in innate
immune cells. The present investigation shows a decrease
of Hsp60 in patients with ITP. Whether the decrease in
Hsp60 occurs before or during its pathogenesis and is an
inducing factor or simply an effect is unknown.
Given the presence of significant differences in Hsp levels
and since the immune response to Hsps can be modu-
lated, modifying the immune response to Hsps may be a
potential new treatment option for patients with ITP.
However at this stage the possible roles of Hsps in the
etiopathogenesis or treatment of ITP remain to be further
investigated.
The present study also shows that antibodies against the
inducible Hsp71 are particularly prevalent in pediatric
patients with ITP. 51.7% of patients had antibodies to
Hsp71 and more than half of those were still positive at
dilutions of 1:80. Berchtold et al. [1] reported that rates of
autoantibodies against platelet membrane glycoproteins
in children with acute and chronic ITP were 26.7%, 58.3%
respectively. Thus the high prevalence of antibodies to
Hsp71 is significant and merits further analysis consider-
ing that the diagnosis for ITP is basically based on exclu-
sion [8]. Some possible reasons for the production of
autoantibodies against Hsps are: 1) genetic factors; 2)
viral infection; 3) denaturation and release of Hsps as a
result of cell damage and 4) the presence of anti-specific
lymphocytes. No obvious genetic diseases were docu-
mented in the pediatric patients with ITP. However, there
were frequent histories of viral or bacterial infection and
treatment with some drugs in pediatric patients before the
occurrence of ITP.
Conclusions
Many investigations suggest that autoantibodies against
Hsps are important in the generation, formation and
prognosis of diseases [28-31,34,48]. Our previous results
show that the high prevalence of antibodies against
Hsp71 in benzene-poisoned workers was associated with
a decrease in white blood cells and with an increase in
activities of serum superoxide dismutase and lymphocyte
DNA damage [28]. There is an immunological cross-reac-
tion between microorganisms and autoantigens of
human as Hsps show a high degree of amino acid
sequence homology between different species from
prokaryotes to humans [48]. Gross et al. [49] showed that
a 66 kDa protein purified from rabbit reticulocyte lysate,
which seems to be involved in platelet destruction, could
promote the recycling of Hsp70. However, the mode of
action of autoantibody is complex, involving modulation
of the expression and function of Fc receptors, interfer-
ence with the activation of complement and the cytokine
network, provision of antiidiotypic antibody, and effects
on the activation, differentiation, and effector functions of
T and B cells [50]. Therefore it will be important to
understand the mechanisms involved in the generation of
antibodies against both Hsp71 and platelets, and toBMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/1
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understand their role in the pathogenesis of ITP, and
whether they can be used for diagnosis, prognosis and/or
treatment of ITP.
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